Abstract The aim of this study is to evaluate experiences about diagnosis, follow-up, and treatment of necrotizing fasciitis (NF) patients who admitted to our hospital. The records of patients who had a diagnosis of NF that referred to our hospital between 01.01.2017 and 01.01.2020 were retrospectively analyzed. Patients' demographic feature, additional disease, number of operations, length of hospital stays, and responses for treatment was evaluated. All of 20 patients with NF were followed up and treated at our hospital. We found 15 (75%) of the patients were male and 5 (25%) were female. The mean age of the patients was 53 (min: 28 - max: 80). While nine (45%) of patients had diabetes mellitus. Concerning the site of infection, 13 (65%) patients had abdominal wall - (NF of the anterior, lateral, and posterior regions), the four (20%) patients of NF involved the chest wall- (NF of the anterior and posterior regions), three (15%) patients’ perianal region with Fournier’s gangrene (secondary to NF). In 75%of patients received double antibiotic (ceftriaxone + metronidazole combination) therapy. Then, the majority of patients were exposed to lots of debridement and diversion colostomy, ranging from 1 to 6 surgeries (mean being two operations). Negative pressure wound closure was applied to 17 (85%) of the patients after debridement and three (15%) of the patients were treated with open dressing. Skin grafting was tackled in our hospital for 13 of these patients while four (31%) of the patients were treated with surgical flap methods. The length of hospital stay varies from 90 days to one day. This time was 37 (1-90). Mortality in this study was found to be 30%- one patient dying on the day of admission after the broad debridement. NF is a malady that is often related with mortality when it is not treated. In many patients, are immunosuppressed and that's why diagnosis can be delayed. In patients with early diagnosis, fast and broad debridement for treatment can achieve enough outcomes. Özet Hastanemize başvuran nekrotizan fasiit (NF)’li hastaların tanı, takip ve tedavisi ile ilgili deneyimlerimizi değerlendirmekti. 01.01.2017 ve 01.01.2020 tarihleri arasında hastanemize başvuran NF tanısı alan hastaların kayıtları retrospektif olarak incelendi. Hastaların demografik özellikleri, ek hastalıkları, ameliyat sayıları, hastanede kalış süreleri ve tedaviye yanıtları değerlendirildi. Toplam 20 NF hastası takip ve tedavi edildi. Hastaların 15'i (%75) erkek, beşi (%25) kadın idi. Yaş ortalaması 53 (minimum: 28 - maksimum: 80) idi. Hastaların 9'unda (%45) diabetes mellitus vardı. Enfeksiyon yeri ile ilgili olarak, 13 (%65) hastada karın duvarı - (ön, lateral ve arka bölgelerin NF'si), dört (%20) NF hastasında göğüs duvarı- (ön ve arka bölgelerin NF'si) vardı ), üç (%15) hasta perianal bölge ile birlikte Fournier gangreni (NF'ye sekonder Fournier gangreni) mevcuttu. Hastaların %75'i ikili antibiyotik (seftriakson + metronidazol kombinasyonu) tedavisi aldı. Tanıdan sonra çoğunlukla 1 ila 6 ameliyat arasında değişen ortalama debridmanlara ve diversiyon kolostomisi yapıldı. Debridman sonrası 17 (%85) hastaya negatif basınçlı yara kapatma yöntemi uygulandı ve üç (%15) hastaya açık pansuman uygulandı ve sekonder iyileşmeye bırakıldı. Bu hastaların 13'üne hastanemizde deri greftleme uygulandı, dördüne (%31) cerrahi flep yöntemi uygulandığı görüldü. Yatış günlerinin sayısı 1 gün ila 90 gün aralığında değişiyordu. Hastanede ortalama kalış süresi 37 (1-90) gün idi. Bu çalışmada mortalite %30 olarak bulundu - bir hastada yoğun debridmandan sonra yatışının birinci gününde mortalite gelişti. NF, tedavi edilmediğinde mortalite ile ilişkili bir hastalıktır. Birçok hastada, bağışıklık sistemi baskılanır ve bu nedenle tanı gecikebilir. Erken tanı alan hastalarda, tedavi için hızlı ve geniş debridman yeterli sonuçlara ulaştırabilir.

{"references": ["1. Sarkut P, I\u015f\u0131k \u00d6, \u00d6zt\u00fcrk E, G\u00fclc\u00fc B, Ercan \u0130, Y\u0131lmazlar T. Gender does not affect the prognosis of Fournier's gangrene: a case-matched study. Ulus Travma Acil Cerrahi Derg 2016; 22(6): 541-4.", "2. Sehmi S, Osaghae S. Type II diabetes mellitus: new presentation manifesting as Fournier's gangrene. JRSM Short Rep 2011; 2(6): 51.", "3. Heijkoop B, Parker N, Spernat D. Fournier's gangrene: not as lethal as previously thought? A case series. ANZ J Surg 2019; 89(4): 350-2.", "4. Erichsen Andersson A, Egerod I, Knudsen VE, Fagerdahl AM. Signs, symptoms and diagnosis of necrotizing fasciitis experienced by survivors and family: a qualitative Nordic multi-center study. BMC Infect Dis 2018; 18(1): 429.", "5. Khalid M, Junejo S, Mir F. Invasive Community Acquired Methicillin-Resistant Staphylococcal Aureus (CA-MRSA) Infections in Children. J Coll Physicians Surg Pak 2018; 28(9): S174-7.", "6. Fernando SM, Tran A, Cheng W, Rochwerg B, Kyeremanteng K, Seely AJE, et al. Necrotizing Soft Tissue Infection: Diagnostic Accuracy of Physical Examination, Imaging, and LRINEC Score: A Systematic Review and Meta-Analysis. Ann Surg 2019; 269(1): 58-65.", "7. Fais P, Viero A, Viel G, Giordano R, Raniero D, Kusstatscher S, et al. Necrotizing fasciitis: case series and review of the literature on clinical and medico-legal diagnostic challenges. Int J Legal Med 2018; 132(5): 1357-66.", "8. Ya\u015far NF, Uyla\u015f MU, Badak B, Bilge U, \u00d6ner S, \u0130htiyar E, \u00c7a\u011fa T, Pa\u015fao\u011flu E. Can we predict mortality in patients with necrotizing fasciitis using conventional scoring systems? Ulus Travma Acil Cerrahi Derg 2017; 23(5): 383-8.", "9. Naseer U, Steinbakk M, Blystad H, Caugant DA. Epidemiology of invasive group A streptococcal infections in Norway 2010-2014: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 2016; 35(10): 1639-48."]}

Nekrotizan Fasiit Tanısı Olan Yetişkin Hastaların Değerlendirilmesi: Üç Yıllık Deneyim. [ High resolution figures, metrics, and more: http://lifemedsci.com/a/2022/1/oz/3.htm ] [ This article previously published as: "Somalia Turkey Journal of Medical Science 2020; 1(1): 6-8." Currently, Somalia Turkey Journal of Medical Science was merged with Life and Medical Sciences. ]